Clinical Efficacy of Ustekinumab in Crohn's Disease

Inclusion Criteria: * Patients aged 18 years and older; * Patients who were first prescribed Ustekinumab between January 1 and December 31, 2024 * Patients who provided written informed consent to participate in the study Exclusion Criteria: * Contraindications to the use of the drug Ustekinumab per the current instructions: * Clinically significant active infection (active tuberculosis, active viral hepatitis); * Pregnancy and lactation; * A history of clinically significant, in the opinion of the investigator, psychiatric disorders that may interfere with the study procedures and compliance with the drug regimen; * Ulcerative colitis; * Malignant gastrointestinal diseases in history or at the time of inclusion in the study; * Decompensated chronic diseases of the liver, kidneys, cardiovascular system, systemic vasculitis, diabetes mellitus; * Abuse of alcohol or psychoactive drugs within 1 year before the start of this study (as reported by the patient); * Participation in an interventional clinical trial.